Q2 Earnings Estimate for Chemours Issued By Zacks Research

The Chemours Company (NYSE:CC) – Equities researchers at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for Chemours in a research note issued to investors on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the specialty chemicals company will post earnings of $0.47 per share for the quarter, down from their previous forecast of $0.58. The consensus estimate for Chemours’ current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours’ Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at $0.34 EPS, FY2025 earnings at $1.46 EPS, Q1 2026 earnings at $0.38 EPS, Q2 2026 earnings at $0.67 EPS, FY2026 earnings at $2.24 EPS, Q1 2027 earnings at $0.53 EPS and FY2027 earnings at $2.57 EPS.

Other analysts have also issued research reports about the company. Morgan Stanley lowered their price target on Chemours from $22.00 to $15.00 and set an “equal weight” rating for the company in a report on Monday, May 12th. Mizuho set a $15.00 target price on Chemours in a report on Tuesday, April 15th. Truist Financial lowered their price objective on Chemours from $27.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, April 14th. BMO Capital Markets lowered their price objective on Chemours from $34.00 to $27.00 and set an “outperform” rating for the company in a research report on Wednesday, February 19th. Finally, UBS Group reduced their target price on Chemours from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Chemours currently has an average rating of “Hold” and a consensus target price of $17.56.

Chemours Trading Down 0.1%

CC opened at $11.17 on Wednesday. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of 19.60 and a beta of 1.76. The stock’s 50 day moving average price is $12.21 and its 200-day moving average price is $16.19. Chemours has a one year low of $9.33 and a one year high of $28.86. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68.

Chemours (NYSE:CC) last released its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.06). The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.36 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.32 EPS.

Chemours Announces Dividend

The firm also recently declared a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours’s dividend payout ratio is presently 175.00%.

Hedge Funds Weigh In On Chemours

Institutional investors and hedge funds have recently modified their holdings of the business. Norges Bank acquired a new stake in Chemours in the 4th quarter worth about $30,702,000. Millennium Management LLC boosted its holdings in shares of Chemours by 60.4% during the 1st quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company’s stock worth $54,428,000 after purchasing an additional 1,515,520 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Chemours by 8.3% during the 1st quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company’s stock worth $223,069,000 after purchasing an additional 1,263,047 shares during the last quarter. Bank of Montreal Can raised its position in shares of Chemours by 1,496.4% during the 4th quarter. Bank of Montreal Can now owns 953,240 shares of the specialty chemicals company’s stock valued at $16,110,000 after buying an additional 893,530 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of Chemours by 23.8% during the 4th quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company’s stock valued at $73,907,000 after buying an additional 839,849 shares during the period. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.